The Miami-based clinical-stage biotechnology company is focused on developing synthetic therapeutics for difficult-to-treat neurological disorders, with its lead compound BIS-001 in clinical development for refractory forms of epilepsy. Biscayne's unique mechanism of action involves a synthetic form of huperzine A, an acetylcholinesterase inhibitor with high brain penetration. The company's experienced executive team and scientific advisors include highly respected experts studying seizure and other CNS disorders, and Biscayne benefits from the growing entrepreneurial South Florida biomedical sector.